Genmab - ADR
NASDAQ:GMAB
| Market Cap (Intraday) | 28.10B |
| Current PE | 5.03 |
| Forward PE | 79.56 |
| 2yr Forward PE | 58.05 |
| 10-Day MA | $43.03 |
| 50-Day MA | $38.57 |
| 200-Day MA | $37.56 |
Genmab - ADR Stock, NASDAQ:GMAB
Kalvebod Brygge 43, Copenhagen, Capital Region 1560
Phone: +45.70.20.27.28
Number of Employees: 781
Description
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.